Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

They haven't peaked yet.

Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH. The new patent extends Aramchol's patent ...

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Investing.com -- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock gained 3.7% on Thursday after the company announced it received a new patent in South Korea for its lead compound Aramchol in ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Resmetirom maintained meaningful improvements in MASH ...

Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in ...

Oppenheimer increased its target to $650, citing enhanced commercial opportunities for Rezdiffra. Truist Securities raised its target to $640, reflecting confidence in Rezdiffra’s potential for ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.